Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-07-28
2010-12-14
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024300
Reexamination Certificate
active
07851162
ABSTRACT:
The present invention relates to methods and kits for determining a predisposition and surveillance protocols for developing cancer of various sites due to specific mutation in at least one allele of CHEK2 gene and/or at least one allele of NOD2gene and/or at least one allele of CDKN2A gene.
REFERENCES:
patent: 2002/0004206 (2002-01-01), Berger et al.
patent: 2003/0138928 (2003-07-01), Carson et al.
patent: 2003/0175721 (2003-09-01), Box et al.
patent: WO 99/29903 (1999-06-01), None
patent: WO 2005/068659 (2005-07-01), None
Lakatos, Peter Laszlo et al. Common NOD2/CARD15 variants are not assoicated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. 2007. BMC Cancer. vol. 7 No. 54 pp. 1-5.
Magnowski P et al. The 3020insC NOD2 gene mutation in patients with ovarian cancer. 2008 Ginekol Pol vol. 79 No. 8 pp. 544-549.
Berns, Emjj et al. Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. 1995. British Journal of Cancer vol. 72 pp. 964-967.
The Gene Card for NOD2 found online at http://www.genecards.org/cgi-bin/carddisp.pl?gene=NOD2&search=nod2 and accessed Feb. 12, 2010.
The Gene Card for CDKN2A found online at http://www.genecards.org/cgi-bin/carddisp.pl?gene=CDKN2A&search=cdkn2a and accessed Feb. 12, 2010.
International Search Report issued by the International Searching Authority (ISA/EP) on Jul. 28, 2005 in connection with PCT International Application No. PCT/PL2005/000006, filed Jan. 15, 2005.
International Preliminary Report on Patentability issued Jul. 17, 2006 in connection with PCT International Application No. PCT/PL2005/000006, filed Jan. 15, 2005.
Written opinion of the International Searching Authority issued on Jul. 15, 2006 in connection with PCT International Application No. PCT/PL2005/000006.
Examination Report issued Nov. 5, 2009 in connection with European Patent Application No. 05704666.6.
May 14, 2010 Reply to the Examination Report issued Nov. 5, 2009 in connection with European Patent Application No. 05704666.6.
Seppälä, E.H., et al. (2003) “CHEK2 variants associate with hereditary prostate cancer,”British Journal of Cancer89:1966-1970.
Meijers-Heijboer, Hanne, et al. (2002) “Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutation,”Nature Genetics31:55-59.
Vahteristo, Pia, et al. (2002) “A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer,”American Journal of Human Genetics71:432-438.
Huzarski, Tomasz, et al. (2005) “Pathology of breast cancer in women with constitutional CHEK2 mutations,”Breast Cancer Research and Treatment90:187-189.
Cybulski, Cezary, et al. (2004) “A novel founder CHEK2 mutation is associated with increased prostate cancer risk,”Cancer Research64:2677-2679.
File History of U.S. Appl. No. 11/037,657, filed Jan. 18, 2005.
Bell et al., Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome, (1999) Science, vol. 386, pp. 2528-2531.
Dong et al., “Mutations in CHEK2 Associated with Prostate Cancer Risk”, (2003) American Journal of Human Genetics, vol. 72, pp. 270-280.
Dufault et al., “Limited International Relevance of the CHEK2 gene in hereditaty breast cancer”, International Journal of Cancer, vol. 110, pp. 320-325, Pub online Feb. 27, 2004.
Ingvarsson et al., “Mutation analysis of the CHK2 gene in breast carcinoma and other cancers”, (2002), Breast Cancer Research, vol. 4, pp. 1-6.
Verhagen, A., “Is the p value really so significant”, (2004), Australian Journal of Physiotherapy, vol. 50, pp. 261-262.
Cybulski Cezary
Dêbniak Tadeusz
Kurzawski Grzegorz
Lubiñski Jan
Suchy Janina
Cooper & Dunham LLP
Gershik Gary J.
Myers Carla
Shaw Amanda
LandOfFree
Determining a predisposition to cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determining a predisposition to cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determining a predisposition to cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207792